Kawasaki disease shock syndrome in the COVID-19 pandemic

Luisa B. Gámez-González1, Moises J. Ramírez-López2, Marcela Colmenero-Rascón3 and Marco A. Yamazaki-Nakashimada4

1Immunology Department, Hospital Infantil de Especialidades de Chihuahua, Chihuahua, Mexico; 2Department of Infectious Diseases, Hospital Infantil de Especialidades de Chihuahua, Chihuahua, Mexico; 3Cardiology Department, Hospital Angeles Chihuahua, Chihuahua, Mexico and 4Immunology Department, Instituto Nacional de Pediatría, Mexico City, Mexico

Abstract

Multisystem inflammatory syndrome in children is a new entity in association with SARS-CoV2. Clinical features of Kawasaki disease were noted from the first reported cases of MIS-C. Before the COVID-19 pandemic, Kawasaki disease shock syndrome was considered to be a distinct and unique form of KD. We present a representative case that prove the current difficulty in clearly distinguishing MIS-C from pre-COVID-19-KDSS and emphasise the overlap of the diagnostic criteria.

At the end of April, 2020, an alert was sent out about severe paediatric cases presenting with shock that were possibly related to SARS-CoV-2.1 Clinical features of Kawasaki disease were noted from the first reported cases.1 This was considered to be a new syndrome and was named as multisystem inflammatory syndrome in children. In contrast to pre-COVID-19 habitual KD, this systemic inflammation syndrome predominantly affects older children, particularly of African descendants and Hispanic ethnicities. MIS-C frequently presents with gastrointestinal manifestations and myocardial involvement and requires aggressive treatment.1 There is no clear distinction between MIS-C and pre-pandemic KD shock syndrome. The following is a representative case that supports this statement.

Case report

A 5-year-old boy presented with a high fever and abdominal pain accompanied by a skin rash. He had COVID-19 contact within his family in the previous month. On physical examination, he was febrile and hypotensive and presented with bilateral conjunctival injection, urticarial exanthema of the trunk and extremities, redness of the lips, and left cervical lymphadenopathy. Laboratory tests revealed haemoglobin 10.51 g/dl, leukocytes 5290 cells/μl, lymphocytes 2200 cells/μl, albumin 3.3 g/dl, platelet count 582 × 10^9/L, elevated CRP 168 mg/L, elevated D-dimer 2590 ng/ml, elevated CK-MB (20.6 U/L) and NT-proBNP (1550 pg/ml and 3950 pg/ml), TGO 117 IU/L, TGP 163 IU/L, and interleukin-6 79.6 pg/ml. SARS-CoV-2 immunoglobulin G testing was positive. The echocardiographic evaluation showed normal biventricular systolic function but identified left coronary artery dilation of 4.5 mm (z score: 4.36). He was admitted to the ICU and was treated with intravenous immunoglobulin 2 g/kg, methylprednisolone 2 mg/kg/day, low-dose aspirin, and enoxaparin.

Discussion

KD presents more commonly in children with Asian ancestry, and surprisingly, MIS-C is rare in Asians, the latter more is commonly reported in children of African ancestry and Hispanic.1,2 In the seminal paper of KDSS by Kaneyage et al. in San Diego, Hispanic patients were overrepresented with no Asians.3 Before the COVID-19 pandemic, KDSS was considered to be a distinct and unique form of KD.3 KDSS is defined as an episode during acute KD of hypotension and shock requiring volume expanders, infusion of vasoactive agents, or transfer to the ICU. KDSS differs from haemodynamically stable KD in terms of older age, frequent gastrointestinal manifestations, neurological manifestations, severe cardiac dysfunction, pericarditis, hypoalbuminemia, hyponatremia, and thrombocytopenia, with higher levels of CRP and troponin, all features are encountered in MIS-C.5 In PP-KDSS, gastrointestinal manifestations were present in 74.6% of the patients. Patients with MIS-C often present with an acute abdomen mimicking appendicitis.1 Coronary artery dilation or aneurysms have been described in 6–24% of patients with MIS-C. Echocardiographic include valve regurgitation, pericardial effusion, and marked LV dysfunction, again paralleling the course of PP-KDSS.1 Hypercoagulability with
abnormalities in the coagulation cascade has been noted with elevated levels of D-dimers and fibrinogen. Notwithstanding, these laboratory findings are non-specific and are altered in PP-KDSS. Patients with MIS-C often present with thrombocytosis in the convalescent phase. Recently, superantigen activity of SARS-CoV2 has been implicated in the pathogenesis of MIS-C, similar to toxic shock syndrome. In PP-KDSS, TSS-1 was the most frequent diagnosis at the time of admission. Superantigens have long been implicated in KD pathophysiology. In PP-KDSS, superantigens were implicated contrasting to hemodynamically normal-KD, and have been thought to have a role in this presentation of KD. SARS-CoV2 has been shown to infect endothelial cells leading to endotheliitis. MIS-C share more features with PP-KDSS than with TSS-1, particularly with TSS-1 lacking coronary artery abnormalities (Table 1). Treatment of MIS-C is analogous to KDSS with IVIG, steroids, and biologics. Recently, the presence of SARS-CoV2 in the gastrointestinal tract with a breakdown of intestinal permeability and subsequent trafficking of the virus antigens into the bloodstream has been found. Importantly, treatment with larazotide, a tight junction regulator that improves intestinal permeability, was associated with clinical response in MIS-C. The clinical similarities and response to similar therapy support the notion that MIS-C is part of the KD spectrum, and with all these arguments, the field have concluded that MIS-C may be a new presentation of KD triggered by a single virus. The parallelism of MIS-C with PP-KDSS reflects the racial predisposition, possible similar pathophysiology (superantigens in both), and infectious aetiology of KD located in the GI tract. These cases open research questions such as the genetic susceptibility of MIS-C (as an inborn error of immunity or superantigen and HLA-related) and the presence of an infectious gastrointestinal trigger, the role of superantigens, and the possible efficacy of larazotide in non-SARS-CoV2-KDSS.  

### Table 1. Demographic and clinical characteristics of patients with MIS-C and KDSS.

|                     | MIS-C                                | KDSS                                |
|---------------------|--------------------------------------|-------------------------------------|
| Age                 | 64.5% > 5 years of age               | 44.7% > 5 years of age              |
| Race                | Hispanic, afro descendant             | Hispanic                            |
| Kawasaki disease features | 40%                                 | 100%                                |
| Gl manifestations   | Frequent                             | Frequent                            |
| Neurological symptoms | Frequent                            | Frequent                            |
| Cardiac involvement | Cardiac failure, valvular regurgitation, pericarditis, coronary artery abnormalities (aneurysms less frequent) | Cardiac failure, valvular regurgitation, pericarditis, coronary artery abnormalities (frequent coronary aneurysms) |
| Albumin             | Low                                  | Low                                 |
| D-dimers            | Elevated                             | Elevated                            |
| Platelets           | Low                                  | Low                                 |
| proBNP              | Elevated                             |                                     |
| Ferritin            | Elevated                             |                                     |
| Treatment           | Corticosteroids, IVIG, infliximab, anakinra, tocilizumab, plasmapheresis, larazotide? | Corticosteroids, IVIG, cyclosporin, plasmapheresis, infliximab, anakinra |
| Mortality           | 2%                                   | 6.8%                                |

KDSS = Kawasaki disease shock syndrome, data are from references 2 and 3; MIS-C = Multisystemic inflammatory syndrome in children.

### Financial support
This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

### Conflicts of interest
None.

### References
1. Whittaker E, Bamford A, Kenny J, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020; 324: 259–269. DOI: 10.1001/jama.2020.10369.
2. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360: 1197–1202. DOI: 10.1016/S0140-6736(02)11279-7.
3. Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009; 123: e783–e789.
4. Gamez-Gonzalez LB, Moribe-Quintero I, Cisneros-Castolo M, et al. Kawasaki disease shock syndrome: unique and severe subtype of Kawasaki disease. Pediatr Int 2018; 60: 781–790.
5. Noval Rivas M, Porritt RA, Cheng MH, Bahar I, Arditi M. COVID-19-associated multisystem inflammatory syndrome in children (MIS-C): a novel disease that mimics toxic shock syndrome the superantigen hypothesis. J Allergy Clin Immunol 2021; 147: 57–59. DOI: 10.1016/j.jaci.2020.10.008.
6. Iglesias-Amaya A, Quezada-Ortega G, Godinez-Victoria M, et al. Kawasaki disease shock syndrome: a different subtype of Kawasaki disease? Poster presented in EAP 2019 Congress. Eur J Ped 2019; 178: 1645.
7. Calcattera G, Mehta JI, Fanos V, Bassareo PP. Insights on Kawasaki disease and multisystem inflammatory syndrome: relationship with COVID-19 infection. Editorial Minerva Pediatr (Torino) 2021; 73: 203–208. DOI: 10.23736/S0026-4946.20.06140-X.
8. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417–1418. DOI: 10.1016/S0140-6736(20)30937-5.
9. Yonker LM, Gilboa T, Ogata A, et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J Clin Invest 2021; 131: 149633. DOI: 10.1172/JCI149633.
10. Sancho-Shimizu V, Brodin P, Cobat A, et al. SARS-CoV2-related MIS-C: a key to the viral and genetic causes of Kawasaki disease? J Exp Med 2021; 218: e20210446. DOI: 10.1084/jem.20210446.